biostudies-literatureUnknown11(3)Tang XY<h4>Background</h4>The mechanisms involved in the malignant progression of lung adenocarcinoma (LUAD) are still inconclusive. Fibrinogen-like protein 1 (<i>FGL1</i>) and <i>LAG3</i> are a pair of immune checkpoints that create an inhibitory immune microenvironment in tumors. However, other roles of <i>FGL1</i> in LUAD have not been extensively studied. Our study aims to explore the role of <i>FGL1</i> in the malignant progression of LUAD and to provide new therapeutic targets and strategies for LUAD treatment.<h4>Methods</h4>Differential gene expression of <i>FGL1</i> was analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA), Oncomine, UALCAN, and Gene Expression Omnibus (GEO) databases. A pan-cancer analysis was conducted using the Oncomine, TIMER, and UALCAN databasesTranslational lung cancer research404-419https://www.ebi.ac.uk/biostudies/studies/S-EPMC8988074biostudies-literatureThe downregulation of fibrinogen-like protein 1 inhibits the proliferation of lung adenocarcinoma via regulating <i>MYC</i>-target genes.PMC8988074Xiong YLHan QMalhotra JZheng KFMa NLv YJiang TSun YZhao JBLiu YJTang XYShi APShi XGFrattini MfalseThe downregulation of fibrinogen-like protein 1 inhibits the proliferation of lung adenocarcinoma via regulating <i>MYC</i>-target genes.<h4>Background</h4>The mechanisms involved in the malignant progression of lung adenocarcinoma (LUAD) are still inconclusive. Fibrinogen-like protein 1 (<i>FGL1</i>) and <i>LAG3</i> are a pair of immune checkpoints that create an inhibitory immune microenvironment in tumors. However, other roles of <i>FGL1</i> in LUAD have not been extensively studied. Our study aims to explore the role of <i>FGL1</i> in the malignant progression of LUAD and to provide new therapeutic targets and strategies for LUAD treatment.<h4>Methods</h4>Differential gene expression of <i>FGL1</i> was analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA), Oncomine, UALCAN, and Gene Expression Omnibus (GEO) databases. A pan-cancer analysis was conducted using the Oncomine, TIMER, and UALCAN databases2022-01-01T00:00:00Z2022 Mar2025-04-26T18:35:14.546Z2024-11-21T11:07:46.893ZS-EPMC89880743539956610.21037/tlcr-22-151